Literature DB >> 26099695

Immunogenicity of Newcastle disease virus vectors expressing Norwalk virus capsid protein in the presence or absence of VP2 protein.

Shin-Hee Kim1, Shun Chen1, Xi Jiang2, Kim Y Green3, Siba K Samal4.   

Abstract

Noroviruses are the most common cause of acute gastroenteritis in humans. Development of an effective vaccine is required for reducing their outbreaks. In order to develop a GI norovirus vaccine, Newcastle disease virus vectors, rLaSota and modified rBC, were used to express VP1 protein of Norwalk virus. Co-expression of VP1 and VP2 proteins by Newcastle disease virus vectors resulted in enhanced expression of Norwalk virus VP1 protein and self-assembly of VP1 protein into virus-like particles. Furthermore, the Norwalk virus-specific IgG response induced in mice by Newcastle disease virus vectors was similar to that induced by baculovirus-expressed virus-like particles in mice. However, the modified rBC vector in the presence of VP2 protein induced significantly higher levels of cellular and mucosal immune responses than those induced by baculovirus-expressed VLPs. These results indicate that Newcastle disease virus has great potential for developing a live Norwalk virus vaccine by inducing humoral, cellular and mucosal immune responses in humans.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Newcastle disease virus; Norwalk virus; VP1 protein; Vaccine; Virus-like particles

Mesh:

Substances:

Year:  2015        PMID: 26099695      PMCID: PMC4567445          DOI: 10.1016/j.virol.2015.06.003

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  30 in total

1.  Norwalk virus N-terminal nonstructural protein is associated with disassembly of the Golgi complex in transfected cells.

Authors:  Virneliz Fernandez-Vega; Stanislav V Sosnovtsev; Gaël Belliot; Adriene D King; Tanaji Mitra; Alexander Gorbalenya; Kim Y Green
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

Review 2.  The epidemiology of published norovirus outbreaks: a review of risk factors associated with attack rate and genogroup.

Authors:  J E Matthews; B W Dickey; R D Miller; J R Felzer; B P Dawson; A S Lee; J J Rocks; J Kiel; J S Montes; C L Moe; J N S Eisenberg; J S Leon
Journal:  Epidemiol Infect       Date:  2012-03-26       Impact factor: 2.451

Review 3.  Norwalk virus vaccines: challenges and progress.

Authors:  M K Estes; J M Ball; R A Guerrero; A R Opekun; M A Gilger; S S Pacheco; D Y Graham
Journal:  J Infect Dis       Date:  2000-05       Impact factor: 5.226

4.  Norovirus vaccine against experimental human Norwalk Virus illness.

Authors:  Robert L Atmar; David I Bernstein; Clayton D Harro; Mohamed S Al-Ibrahim; Wilbur H Chen; Jennifer Ferreira; Mary K Estes; David Y Graham; Antone R Opekun; Charles Richardson; Paul M Mendelman
Journal:  N Engl J Med       Date:  2011-12-08       Impact factor: 91.245

5.  Enteric bacteria promote human and mouse norovirus infection of B cells.

Authors:  Melissa K Jones; Makiko Watanabe; Shu Zhu; Christina L Graves; Lisa R Keyes; Katrina R Grau; Mariam B Gonzalez-Hernandez; Nicole M Iovine; Christiane E Wobus; Jan Vinjé; Scott A Tibbetts; Shannon M Wallet; Stephanie M Karst
Journal:  Science       Date:  2014-11-07       Impact factor: 47.728

6.  The 3' end of Norwalk virus mRNA contains determinants that regulate the expression and stability of the viral capsid protein VP1: a novel function for the VP2 protein.

Authors:  Andrea Bertolotti-Ciarlet; Sue E Crawford; Anne M Hutson; Mary K Estes
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

7.  Intranasal administration of a recombinant adenovirus expressing the norovirus capsid protein stimulates specific humoral, mucosal, and cellular immune responses in mice.

Authors:  Li Guo; Jianwei Wang; Hongli Zhou; Hongli Si; Min Wang; Jingdong Song; Bingjuan Han; Yi Shu; Lili Ren; Jianguo Qu; Tao Hung
Journal:  Vaccine       Date:  2007-12-04       Impact factor: 3.641

8.  Norovirus and medically attended gastroenteritis in U.S. children.

Authors:  Daniel C Payne; Jan Vinjé; Peter G Szilagyi; Kathryn M Edwards; Mary Allen Staat; Geoffrey A Weinberg; Caroline B Hall; James Chappell; David I Bernstein; Aaron T Curns; Mary Wikswo; S Hannah Shirley; Aron J Hall; Benjamin Lopman; Umesh D Parashar
Journal:  N Engl J Med       Date:  2013-03-21       Impact factor: 91.245

9.  Recombinant Norwalk virus-like particles administered intranasally to mice induce systemic and mucosal (fecal and vaginal) immune responses.

Authors:  R A Guerrero; J M Ball; S S Krater; S E Pacheco; J D Clements; M K Estes
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

10.  Foodborne illness acquired in the United States--major pathogens.

Authors:  Elaine Scallan; Robert M Hoekstra; Frederick J Angulo; Robert V Tauxe; Marc-Alain Widdowson; Sharon L Roy; Jeffery L Jones; Patricia M Griffin
Journal:  Emerg Infect Dis       Date:  2011-01       Impact factor: 6.883

View more
  4 in total

Review 1.  Plant Viruses as Nanoparticle-Based Vaccines and Adjuvants.

Authors:  Marie-Ève Lebel; Karine Chartrand; Denis Leclerc; Alain Lamarre
Journal:  Vaccines (Basel)       Date:  2015-08-05

2.  Recombinant Newcastle disease virus (NDV) expressing Duck Tembusu virus (DTMUV) pre-membrane and envelope proteins protects ducks against DTMUV and NDV challenge.

Authors:  Minhua Sun; Jiawen Dong; Linlin Li; Qiuyan Lin; Junying Sun; Zhicheng Liu; Haiyan Shen; Jianfeng Zhang; Tao Ren; Chunhong Zhang
Journal:  Vet Microbiol       Date:  2018-03-28       Impact factor: 3.293

3.  Reverse Genetics of Newcastle Disease Virus.

Authors:  Stivalis Cardenas-Garcia; Claudio L Afonso
Journal:  Methods Mol Biol       Date:  2017

Review 4.  Newcastle Disease Virus as a Vaccine Vector for Development of Human and Veterinary Vaccines.

Authors:  Shin-Hee Kim; Siba K Samal
Journal:  Viruses       Date:  2016-07-04       Impact factor: 5.048

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.